* Note: Prices are in Million (M) USD.
Description:
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $126 M
Debt : $270 M
EBITDA : $-78 M
Net Debt (Debt - Cash): $144 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health Care
Industry: Biotechnology
Based on industry, 5 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 4.56
Since Forward PE Ratio is less than 15, 5 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $-83 M
Average Revenue: $166 M
Revenue Converted To Free Cash Flow (%): -50%
Avg Free Cash Flow Growth Per Year (Last 5 Years): 62.70%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $267 M
Revenue 4 Years Ago (2020-12-31): $476 M
Last 5 Years Average Revenue Growth: -9%
Since Revenue Growth is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $115 M
Share Count 5 Years Ago (2020-12-31): $83 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $0.03
Trailing 12-Month Earnings Per Share (EPS): $0.51
Average Earnings Per Share (EPS): $0.27
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: -301%
Since Average ROE is negative, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $1
52-Week Low: $1
Threshold Price (15% Above 52-Week Low): $1
Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $112 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based the market cap, we recommend do not exceed 0.5% exposure of Total Portfolio.
Value-Trade has assigned 12 points to above Coherus BioSciences Inc (CHRS) stock.
Last 2 Years Avg PE 12.52, Fair Value PE 20, Industry Based PE 20. Based on these 3 values, average assigned is 17.51.
Value-Trades has assined P/E value 17.51. Since an average (Current Year EPS + Next Year EPS) earning per share is $0.27.
The fair value of Coherus BioSciences Inc (CHRS) stock should be (17.51 x $0.27) = $4.73
